Literature DB >> 16341041

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations.

P Cornillet-Lefebvre, W Cuccuini, V Bardet, J Tamburini, L Gillot, N Ifrah, P Nguyen, F Dreyfus, P Mayeux, C Lacombe, D Bouscary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16341041     DOI： 10.1038/sj.leu.2404054

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 3.  Expression of different functional isoforms in haematopoiesis.

Authors:  Godfrey Grech; Joel Pollacco; Mark Portelli; Keith Sacco; Shawn Baldacchino; Justine Grixti; Christian Saliba
Journal:  Int J Hematol       Date:  2013-12-01       Impact factor: 2.490

Review 4.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

5.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Authors:  Nicolas Chapuis; Jérôme Tamburini; Pascale Cornillet-Lefebvre; Lucile Gillot; Valérie Bardet; Lise Willems; Sophie Park; Alexa S Green; Norbert Ifrah; François Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 6.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  The role of translation initiation regulation in haematopoiesis.

Authors:  Godfrey Grech; Marieke von Lindern
Journal:  Comp Funct Genomics       Date:  2012-05-09

8.  p110δ PI3 kinase pathway: emerging roles in cancer.

Authors:  Niki Tzenaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2013-03-01       Impact factor: 6.244

9.  Constitutive AKT activation in follicular lymphoma.

Authors:  Ouardia I Yahiaoui; Jacques A Nunès; Céline Castanier; Raynier Devillier; Florence Broussais; Aurélie J Fabre; Dalila Naimi; Réda Bouabdallah; Daniel Olive; Luc Xerri
Journal:  BMC Cancer       Date:  2014-08-05       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.